JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Novel Nonsense Variants c.58C>T (p.Q20X) and c.256G>T (p.E85X) in the CHEK2 Gene Identified dentified in Breast Cancer Patients from Balochistan
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Novel Nonsense Variants c.58C>T (p.Q20X) and c.256G>T (p.E85X) in the CHEK2 Gene Identified dentified in Breast Cancer Patients from Balochistan
Baloch, Abdul Hameed; Khosa, Ahmad Nawaz; Bangulzai, Nasrullah; Shuja, Jamila; Naseeb, Hafiz Khush; Jan, Mohammad; Marghazani, Illahi Bakhsh; Kakar, Masood-ul-Haq; Baloch, Dost Mohammad; Cheema, Abdul Majeed; Ahmad, Jamil;
  PDF(new window)
 Abstract
Breast cancer is the most commonly occurring and leading cause of cancer deaths among women globally. Hereditary cases account 5-10% of all the cases and CHEK2 is considered as a moderate penetrance breast cancer risk gene. CHEK2 plays a crucial role in response to DNA damage to promote cell cycle arrest and repair DNA damage or induce apoptosis. Our objective in the current study was to analyze mutations in the CHEK2 gene related to breast cancer in Balochistan. A total of 271 individuals including breast cancer patients and normal subjects were enrolled. All 14 exons of CHEK2 were amplified and sequenced. The majority of the patients (>95%) had invasive ductal carcinomas (IDCs), 52.1% were diagnosed with tumor grade III and 56.1% and 27.5% were diagnosed with advance stages III and IV. Two novel nonsense variants i.e. c.58C>T (P.Q20X) and c.256G>T (p.E85X) at exon 1 and 2 in two breast cancer patients were identified in the current study. Both the variants identified were novel and have not been reported elsewhere.
 Keywords
Breast cancer;CHEK2 gene;novel nonsense variants;Balochistan;
 Language
English
 Cited by
 References
1.
Willems PG (2007) Susceptibility genes in breast cancer: more is less? Clin Genet. 72, 493-6. crossref(new window)

2.
Panda S, Isbatan A, Adami GR (2008) Modification of the ATM/ATR directed DNA damage response state with aging and long after hepatocyte senescence induction in vivo. Mech Ageing Dev, 129, 332-40. crossref(new window)

3.
Jemal A, Bray F, Center MM, et al (2011) Global cancer statistics. CA Cancer J Clin, 61, 69-90. crossref(new window)

4.
Baloch AH, Daud S, Raheem N, et al (2014). Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin. Mol Biol Rep, 41,1103-7. crossref(new window)

5.
Meijers-Heijboer H, van den Ouweland A, Klijn J, et al (2002) CHEK2-breast cancer consortium: low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet, 31, 55-59. crossref(new window)

6.
Renwick A, Thompson D, Seal S, et al (2006). Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR, Rahman N: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet, 38, 873-5. crossref(new window)

7.
Seal S, Thompson D, Renwick A, et al (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 38, 1239-41. crossref(new window)

8.
Rahman N, Seal S, Thompson D, et al (2007). Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 39, 165-7. crossref(new window)

9.
Vahteristo P, Bartkova J, Eerola H, et al (2002). A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 71,432-8. crossref(new window)

10.
Oldenburg RA, Kroeze-Jansema K, Kraan J, et al (2003). The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res, 63, 8153-7.

11.
Dong X, Wang L, Taniguchi K, et al (2003). Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet, 72, 270-80. crossref(new window)

12.
Cybulski C, Gorski B, Huzarski T, et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet, 75, 1131-5. crossref(new window)

13.
Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene, 25, 5912-9. crossref(new window)

14.
Walsh T, Casadei S, Lee MK, et al (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA, 108, 18032-7. crossref(new window)

15.
Zeng Y, Forbes KC, Wu Z, et al (1998). Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature, 395, 507-10. crossref(new window)

16.
Lee JS, Collins KM, Brown AL, Lee CH, Chung JH (2000). hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature. 404, 201-04. crossref(new window)

17.
Chehab NH, Malikzay A, Appel M, Halazonetis TD (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev, 14, 278-288.

18.
Falck J, Mailand N, Syljuasen RG, et al (2001). The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature, 410, 842-7. crossref(new window)

19.
Matsuoka S, Rotman G, Ogawa A, et al (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA, 97, 10389-94. crossref(new window)

20.
Bartek J, Lukas J (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, 421-9. crossref(new window)

21.
Wu X, Webster SR and Chen J (2001). Characterization of tumorassociated chk2 mutations. J Biol Chem, 276, 2971-74. crossref(new window)

22.
Weischer M, Bojesen SE, Ellervik C, et al (2008). CHEK2_1100delC genotyping for clinical assessment of breast risk: meta analysis of 26,000 patient cases and 27,000 control. J Clin Oncol, 26, 542-8. crossref(new window)

23.
Fletcher O, Johnson N, Dos Santos Silva I, et al (2009). Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev, 18, 230-4. crossref(new window)

24.
Narod SA (2010) Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin Genet, 78, 1-7.

25.
Le Calvez-Kelm F, Lesueur F, Damiola F, et al (2011). Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res, 13, 6.

26.
Available online: Globocan (2012). http://globocan.iarc.fr/Default.aspx.

27.
Curado MP, Edwards B, Shin HR, et al (2007)/ eds. Cancer incidence in five continents. Vol. IX. Lyon, France: International Agency for Research on Cancer, 2007. (IARC scientific publications no. 160.) (Accessed December 27, 2007, at http://www-dep.iarc.fr/.)

28.
Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al (2005). ABREAST investigators: the global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 6, 391-401 crossref(new window)

29.
Ries LAG, Eisner MP, Kosary CL (2003) Cancer Statistics Review, 1975-2000. Bethesda, MD. National Cancer Institute.

30.
Rowan T. Chlebowski, Lewis H, et al (2009). Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. N Engl J Med, 360, 573-587. crossref(new window)

31.
Chlebowski RT, Kuller LH, Prentice RL, et al (2009). Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med, 360, 573-87. crossref(new window)

32.
Gathani T, Ali R, Balkwill A, et al (2014) Ethnic differences in breast cancer incidence in England are due to differences in known risk factors for the disease: prospective study. Br J Cancer, 110, 224-229. crossref(new window)

33.
Meijers-Heijboer H, van den Ouweland A, Klijn J, et al (2002). CHEK2-breast cancer consortium. low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31, 55-9. crossref(new window)

34.
Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol, 23, 41-8. crossref(new window)

35.
Ludwig J (2008) Personalized therapy of sarcomas: integration of biomarkers for improved diagnosis, prognosis, and therapy Sselection. Curr Oncol Rep. 10, 329-37. crossref(new window)

36.
Baloch A.H, Shuja J, Daud S, et al (2013) Various aspects, patterns and risk factors in breast cancer patients of balochistan. Asian Pac J Cancer Prev, 13, 4013-6.

37.
Desrichard A., Bidet Y, Uhrhammaer N and Bignon Yves-J (2011). CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res, 13, 119 crossref(new window)

38.
Mohamad S, Nurismah Md Isa1 N, Muhammad R, et al (2015). Prevalence of CHEK2 gene mutations in multiethniccohorts of breast cancer patients in Malaysia. PLoS ONE, 10, 117104.

39.
Kuusisto KM, Bebel A, Vihinen M, et al (2011) Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation negative breast and/or ovarian cancer individuals. Breast Cancer Res, 13, 20.

40.
Staalesen V, Falck J, Geisler S, et al (2004). Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene, 23, 8535-44. crossref(new window)

41.
Chrisanthar R, Knappskog S, Lokkevik E, et al (2008). CHEK2 Mutations affecting kinase activity together with mutations in tp53indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS ONE, 3, 3062. crossref(new window)